Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 973-981

  Valdez, Benigno C ^a   Murray, David ^b   Nieto, Yago ^a   Li, Yang ^a   Wang, Guiyun ^a   Champlin, Richard E ^a   Andersson, Borje S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

busulfan; clofarabine; DNA alkylating agent; gemcitabine; lymphoma; SAHA

Indexed keywords

ATM PROTEIN; BUSULFAN; CELL PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CLOFARABINE; CYCLIN DEPENDENT KINASE 4; FLUDARABINE; GEMCITABINE; HISTONE H2AX; KRAB ASSOCIATED PROTEIN 1; MYC PROTEIN; PROTEIN P53; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STRUCTURAL MAINTENANCE OF CHROMOSOMES 1 PROTEIN; STRUCTURAL MAINTENANCE OF CHROMOSOMES 3 PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; HISTONE ACETYLATION; HISTONE MODIFICATION; INTRACELLULAR SIGNALING; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ACETYLATION; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DNA DAMAGE; DRUG SYNERGISM; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA; NUCLEOSIDES; TRANSPLANTATION CONDITIONING;

EID: 84859950967     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.634043     Document Type: Article

References (43)

1. Murawski N, Pfreundschuh. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010;11:1074-1085.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
3. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002;346:235-342.
4. Pfreundschuh M, Truemper L, Osterborg A, et al.; MabTh era International Trial Group. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diff use large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
5. Salit RB, Bishop MR, Pavletic SZ. Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma? Curr Hematol Malig Rep 2010;5:229-238.
6. Srivastava S, Jones D, Wood LL, et al. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2011;17:987-994.
7. Suyani E, Sucak GT, Aki SZ, et al. Gemcitabine and vinorelbine combination is eff ective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 2011;90:685-691.
8. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fl udarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002;8:468-476. (Pubitemid 35174820)
9. De Lima M, Couriel D, Th all PF, et al. Once-daily intravenous busulfan and fl udarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104:857-864. (Pubitemid 38970585)
10. Andersson BS, de Lima M, Th all PF, et al. Once daily i.v. busulfan and fl udarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008;14:672-684. (Pubitemid 351664062)
11. Andersson BS, Valdez BC, de Lima M, et al. Clofarabine± fl udarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011;17:893-900.
12. Farag SS, Wood LL, Schwartz JE, et al. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011;25:599-605.
13. Valdez BC, Li Y, Murray D, et al. Th e synergistic cytotoxicity of clofarabine, fl udarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 2011;81:222-232.
14. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 2001;19:21-45.
15. Valdez BC, Andersson BS. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen 2010;51:659-668.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
17. Kastan MB, Lim DS. Th e many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000;1:179-186.
18. Zhou BB, Elledge SJ. Th e DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-439.
19. Kim S-T, Xu B, Kastan MB. Involvement of the cohesion protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev 2002;16:560-570. (Pubitemid 34212489)
20. Ziv Y, Bielopolski D, Galanty Y, et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATMand KAP-1 dependent pathway. Nat Cell Biol 2006;8:870-876. (Pubitemid 44151591)
21. Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-5868. (Pubitemid 28124064)
22. Reinhardt HC, Yaff e MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009;21:245-255.
23. Hirano T. SMC-mediated chromosome mechanics: a conserved scheme from bacteria to vertebrates? Genes Dev 1999;13:11-19. (Pubitemid 29045111)
24. Stursberg S, Riwar B, Jessberger R. Cloning and characterization of mammalian SMC1 and SMC3 genes and proteins, components of the DNA recombination complexes RC-1. Gene 1999;228:1-12. (Pubitemid 29136681)
25. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9:616-627. (Pubitemid 352032926)
26. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies - association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413-5417. (Pubitemid 21914755)
27. Johnstone RW, Wei W, Greenway A, et al. Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene 2000;19:6033-6042. (Pubitemid 32039377)
28. Liu G, Lozano G. p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell 2005;7:113-114. (Pubitemid 40248335)
29. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-414.
30. Grandori C, Cowley SM, James LP, et al. Th e Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-699. (Pubitemid 32037520)
31. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 2010;1815:75-89.
32. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-5552. (Pubitemid 47255934)
33. Scognamiglio A, Nebbioso A, Manzo F, et al. HDAC-class II specifi c inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta 2008;1783:2030-2038.
34. Vaute O, Nicolas E, Vandel L, et al. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res 2002;30:475-481. (Pubitemid 34679609)
35. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437-2441. (Pubitemid 41691565)
36. Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:51-58. (Pubitemid 44322770)
37. Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the longterm outcome. Ann Oncol 2010;21:860-863.
38. Aribi M, Mesli N, Remla N, et al. Gemcitabine and treatment of diff use large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria. J Cancer Res Th er 2010;6:41-46.
39. Nieto Y, Anderlini P, Popat U, et al. Gemcitabine, busulfan and melphalan (GemBuMel) is a new high-dose chemotherapy (HDC) regimen with high activity in refractory Hodgkin's lymphoma (HL) patients receiving an autologous stem-cell transplant (ASCT): a contemporaneous comparison with BEAM and busulfan/melphalan (BuMel). Blood 2010;116(Suppl. 1): Abstract 690.
40. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011;8:85-96.
41. Smith J, Th o LM, Xu N, et al. Th e ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010;108:73-112.
42. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part I: covalent histone modifi cations. Trends Mol Med 2007;13:363-372. (Pubitemid 47385381)
43. van Attikum H, Gasser SM. Crosstalk between histone modifi cations during the DNA damage response. Trends Cell Biol 2009;19:207-217.